Effect of Cabergoline on Weight and Glucose Tolerance
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine
receptor agonist, on body weight and blood glucose in healthy obese adults.
This is a randomized double-blind placebo controlled study. Twenty subjects each will be
randomly assigned either placebo or cabergoline for 16 weeks.
The effect of treatment on body weight and blood glucose and insulin levels will be compared
in the treatment versus the placebo arm.